Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — Bioshares 18th Biotech Summit 2024
20 slides from Racura Oncology's conference presentation, Jul 12, 2024
Slide 1: Race to Present at the Bioshares 18th Biotech Summit
ASX Announcement Ra c e t o P re s e n t a t t h e Bio s h a re s 18 t h Bio t e c h Su m m it 12 July 2024 – Race Oncology Limited (“Race”) is pleased to share a copy of the presentation that will be presented to investors and industry colleagues at the Bioshares 18th Biotech Summit this week in Fr
Slide 2: Release authorisation and contacts
licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com. If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcemen
Slide 3: At the Heart of Cancer Care
J u l y 2 0 2 4 For personal use only AT THE HEART OF CANCER CARE Pete Smith PhD, Executive Director Bioshares 2024 0 1 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749
Slide 4: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E For personal use only The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company). H E A R T THIS IS NOT A PROSPECTUS This presentation is not a prospectus, product disclosure statement or disclosure document for
Slide 5: Cancer survivorship
3 A T T H E H E A R T O F C A N C E R C A R E survivorship Cancer For personal use only
Slide 6: Cancer survivorship – life after treatment
Cancer survivorship – life after treatment A T T H E For personal use only H E A R T New specialties such as cardio- Ageing By 2023, there will be 22.5m cancer oncology are focused on reducing survivors in the US 1 with a 37% increased O F damage caused by treatments risk of cardiovascular disease f
Slide 7: Chemotherapy needs improvement
Chemotherapy needs improvement A T T H E For personal use only H E A R T O F C A N C E R Anthracyclines* are the most widely Current solution – exclude use in used class of chemotherapeutics. high-risk patients and limit C A R E They are highly effective, but can dosing of the drugs cause permanent
Slide 8: Global anthracycline chemotherapy use
Global anthracycline chemotherapy use1 A T T H E For personal use only H E A R T Global anthracycline usage1 FDA approved uses2, 3 Other uses2, 3 Acute lymphocytic Ewing sarcoma Advanced endometrial O F leukemia cancer C A N C E R Acute nonlymphocytic Soft tissue sarcoma Uterine sarcoma leukemia Acu
Slide 9: Clinical development of bisantrene
7 A T T H E H E A R T O F C A N C E R C A R E development of bisantrene Clinical For personal use only
Slide 10: Corporate snapshot
Corporate snapshot A T T H E For personal use only Race Oncology is an ASX-listed, clinical stage biopharmaceutical company with a dedicated mission to be at the H E A R T heart of cancer care. O F C A N C E R Key data Race 12-month trading history C A R E ASX code RAC Share price $1.70 1 Market cap
Slide 11: Bisantrene's history of clinical success
Bisantrene’s history of clinical success A T T H E For personal use only Acute Myeloid Leukaemia H E A R T Breast cancer 1 O F 471 patients across 9 Phase 2 & 3 Approved in France in 1988, but Lederle (Pfizer) ended C A N C E R clinical trials commercial development of bisantrene due to solubility i
Slide 12: Bisantrene + doxorubicin = improved anti-cancer activity
Bisantrene + doxorubicin = A T improved anti-cancer activity 1 T H E For personal use only H E A R T Bisantrene shows potent cell-killing activity against a diverse range of human cancers when used alone and in combination with doxorubicin, the most commonly used anthracycline O F C A N C E R Bisant
Slide 13: Bisantrene + doxorubicin = protecting the heart
Bisantrene + doxorubicin = protecting the heart 1 A T T H E For personal use only H E A R T Bisantrene protects the hearts of mice from permanent damage Vehicle caused by the anthracycline, doxorubicin Bisantrene O F Doxorubicin C A N C E R Heart protection was achieved using higher levels of Dox +
Slide 14: Building on bisantrene's history
Building on bisantrene’s history A T T H E For personal use only H E A R T Race has… O F • Created RC220, a new formulation of bisantrene which is more soluble C A N C E R and can be delivered intravenously 1 • RC220 preserves the PK/PD properties of the earlier clinically C A R E validated formulat
Slide 15: RC220 cardioprotection clinical program
RC220 cardioprotection clinical program A T T H E For personal use only H E A R T An ‘all comers’ Bayesian dose escalation Phase 1a/1b trial of RC220 in any solid tumour patient where anthracycline use is indicated O F Size: 25-50 patients; up to 10 sites in Australia and internationally C A N C E R
Slide 16: Clinical pipeline
Clinical pipeline A T T H E For personal use only H E A R T O F IND C A N C E R Asset Indication Sponsor Discovery Phase 1 Phase 2 Phase 3 Next milestone enabling Chaim Sheba C A R E RC110 Medical Acute Myeloid Leukaemia Phase 2 In final stages of trial Centre, Israel Cardioprotection + m6A RNA + an
Slide 17: Bisantrene Market Potential – World
Bisantrene Market Potential – World A T T H E For personal use only H E A R T Annual revenue generic Annual revenue bisantrene doxorubicin - 20231 cardioprotection + anti-cancer2 O F C A N C E R C A R E US$1.5b US$7b Note: Forecasted revenue reflect a 50% reduction to the physician- stated adoption
Slide 18: Recent & upcoming milestones
Recent & upcoming milestones1 A T T H E For personal use only H E A R T H2 CY2023 / H1 CY2024 H2 CY2024 H1 CY2025 Interim results released from Sheba 2 O F Distinguished Oncologist Daniel Von Additional preclinical results on study of bisantrene RC110 in AML C A N C E R Hoff Joins as Consultant
Slide 19: Key highlights of Race Oncology
Key highlights of Race Oncology A T T H E For personal use only H E A R T Bisantrene – derisked & clinically proven anti-cancer drug offering ~80% chance of O F success - not ~3% common in oncology C A N C E R Solves real & significant health problem – cardiovascular damage caused by C A R E chemoth
Slide 20: Questions
For personal use only Questions Race Oncology A T T H E H E A R T O F C A N C E R C A R E 18